Reporting from ASCO 2023, Rowan Miller discusses practice changing results from the MIRASOL study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian cancer.
Abstract: LBA5507 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression, presented by Kathleen Moore.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology-news/esmo-videos